Pediatric NASH therapies: A speedbump on the road to success

Samir Softic^{1

2

3}, Rohit Kohli⁴

Affiliations

¹ Department of Pediatrics, Division of Pediatric Gastroenterology, University of Kentucky College of Medicine and Kentucky Children's Hospital, Lexington, Kentucky, USA.
² Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
³ Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
⁴ Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital Los Angeles, Los Angeles, California, USA.

Editorial

Samir Softic et al. Hepatology. 2022 Aug.

. 2022 Aug;76(2):292-294.

doi: 10.1002/hep.32322. Epub 2022 Feb 22.

Samir Softic^{1

2

3}, Rohit Kohli⁴

¹ Department of Pediatrics, Division of Pediatric Gastroenterology, University of Kentucky College of Medicine and Kentucky Children's Hospital, Lexington, Kentucky, USA.
² Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
³ Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
⁴ Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital Los Angeles, Los Angeles, California, USA.

No abstract available

Comment on

Randomized placebo-controlled trial of losartan for pediatric NAFLD.
Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, Jain AK, Karpen SJ, Lavine JE, Mohammad S, Miriel LA, Molleston JP, Mouzaki M, Sanyal A, Sharkey EP, Schwimmer JB, Tonascia J, Wilson LA, Xanthakos SA; NASH Clinical Research Network. Vos MB, et al. Hepatology. 2022 Aug;76(2):429-444. doi: 10.1002/hep.32403. Epub 2022 Feb 28. Hepatology. 2022. PMID: 35133671 Free PMC article. Clinical Trial.

1. Radulescu A, Dugan AJ, Killian M, Attia SL, Mouzaki M, Fuchs GJ, et al. Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non-alcoholic fatty liver disease and metabolic dysfunction. Pediatr Obes. 2022;17:e12862.
1. Holterman AX, Guzman G, Fantuzzi G, Wang H, Aigner K, Browne A, et al. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity (Silver Spring). 2013;21:591-7.
1. Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113:1649-59.
1. Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, et al. Randomized placebo-controlled trial of losartan for pediatric nonalcoholic fatty liver disease. Hepatology. 2022;76:429-44.
1. Attia SL, Softic S, Mouzaki M. Evolving role for pharmacotherapy in NAFLD/NASH. Clin Transl Sci. 2021;14:11-9.